Prescribing information

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300mg dose is given as two injections of 150mg or one injection of 300mg. Psoriatic Arthritis: Recommended doses are 300mg in patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders, 150mg in other patients. Can be increased to 300mg based on clinical response. Ankylosing Spondylitis: Recommended dose is 150mg. Can be increased to 300mg based on clinical response. Non-radiographic axial spondyloarthritis: Recommended dose is 150mg.

Introducing the new 300mg autoinjector pen: All the benefits of Cosentyx 300mg in ONE UnoReady® pen1

Image. UNOREADY® 300mg PEN key features

300 mg autoinjector pen with call-out benefits

 

 

UnoReady® 300mg pen:
Similar administration steps as the SensoReady® 150mg pen, with a few differences.1,4,5

 

300 mg autoinjector pen with a list of key features
150 mg autoinjector pen with a list of key features
 
 

The UnoReady® 300mg pen will be available via the homecare channels and your pharmacy.
If you would like to order a demo-kit or for further information on the UnoReady® 300mg pen, please contact us here

*N=37, moderate-to-severe plaque psoriasis patients at Week 28.2
In a clinical study, adverse events with the preferred term injection-site bruising or injection-site pain due to administration of Cosentyx using the UnoReady® pen over 52 weeks.

DMARD, disease-modifying anti-rheumatic drugs; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis.

References

  1. Cosentyx Summary of Product Characteristics.
  2. Novartis data on file. CAIN457A2325 Data Analysis Report. Satisfaction with self-injection. December 2020. 
  3. Novartis data on file. CAIN457A2325 Data Analysis Report. Injection site reaction rate. December 2020.   
  4. Cosentyx EPAR Product Information. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx Accessed February 2021.
  5. Paul C et al. J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090.
Rate this content: 
No votes yet
UK | May 2021 | 108784
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]